Business Information
The principal activity of the group is to research, develop and commercialise pharmaceutical compounds or products. The products are used in the treatment of central nervous system disorders and other areas. The group is currently developing pagoclone for panic and generalized anxiety disorders, trospium for overactive bladder, ip 501 for cirrhosis of the liver, citicoline for ischemic stroke, pro 2000 for the prevention of infection by the human immunodeficiency virus and other sexually transmitted pathogens and dersalazine for inflammatory bowel disease.
|
|
Name |
Title
|
Email
|
| Glenn Cooper | Chmn., CEO | N/A | | Mark Butler | Exec. VP, Chief Administrative Officer, General Counsel | N/A | | Thomas Farb | COO, Pres. | N/A | | Bobby Sandage | Exec. VP - Research, Development, Chief Scientific Officer | N/A | | Brooke Wagner | VP - Corporate Communications | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 50,452 | (50,554) | | 2005 | 33,336 | (53,218) | | 2004 | 18,726 | (68,212)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
